However, on 10/10/2013, SK announced it had acquir
Post# of 36728
Posted On: 03/07/2014 9:34:56 AM
However, on 10/10/2013, SK announced it had acquired the exclusive license for Dharmanol. That would imply SK is licensee not licensor. I hope BB and/or Benz can clarify these issues.
"We are pleased to have acquired this exclusive license to this important new product in the fight against disease using medical cannabis," said Artemus Mayor, President of SK3 Group. "We expect it to be in high demand with collectives and consumers."
LOS ANGELES, CA -- (Marketwired) -- 10/10/2013 -- SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary, Medical Greens, is pleased to announce that it has obtained the exclusive license for Dharmanol™ for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
"We consider this to be a major breakthrough in the treatment of cancer using cannabinoids. The results seen by those groups and individuals promoting the use of what has been dubbed 'Simpson' therapy have been very convincing. The problem, however, has been that many people who are fighting cancer, and have no experience with cannabis, cannot take the emotional and mental effects that come from following the regimen, which requires consumption of a gram of cannabis extract oil every day for several months. This is the equivalent of smoking up to 100 marijuana cigarettes every day. The "high" from the experience is truly overwhelming, and we have seen patients choose to discontinue the therapy, even though doing so likely leads to negative effects on their treatment," said D. Gold, Dr. Apel's partner in development of the process. "Now patients will be able to consume the large doses necessary for this therapy to be effective, with none of the psychoactive side effects that have been such an unforgiving part of the therapy."
Dharmanol™ (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
These tablets will contain an array of the most beneficial non-psychoactive cannabinoids. Each tablet will contain 5 mg. of CBD, 5 mg. of mixed cannabinoids in their non-psychoactive form (known as mixed carboxylates) and 5 mg. of a steam-distilled mixture of the natural terpenes and terpenoids found in cannabis and hemp. The terpene element is thought to be responsible for the increased medicinal efficacy of "whole plant" cannabis preparations.
At the opposite end of the spectrum is using high dosage Dharmanol™ much like the "Simpson" therapy. High doses can be taken daily with no psychoactive effects. On observing the positive results that patients are receiving with standard Simpson therapy, most people studying cannabis medicine agree that if the dose could be increased ten or a hundred times, its already substantial efficacy against cancer will be similarly enhanced. Now this is possible thanks to the removal of the "high" from the cannabinoids in the production of Dharmanol™.
"We believe that we have crossed the bridge, so to speak, between the incredible medicinal efficacy of the cannabis plant and the world of nutraceutical supplements. Now people will be able to benefit from the substantial health-giving aspects of the cannabis plant, without the 'high' and related side effects that have kept this wonderful herb from entering the world of mainstream medicine. Dr. Apel and I would like to thank all those who have worked so hard on this project to help us develop this new technology," said Gold.
"We are pleased to have acquired this exclusive license to this important new product in the fight against disease using medical cannabis," said Artemus Mayor, President of SK3 Group. "We expect it to be in high demand with collectives and consumers."
Dharmanol™ tablets will be distributed through the collectives managed by or partnered with Medical Greens, which currently has products in over 75 collectives in the state of California. The Manufacturer's Suggested Retail Price will be $25.00 per bottle for 8 capsules.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
"We are pleased to have acquired this exclusive license to this important new product in the fight against disease using medical cannabis," said Artemus Mayor, President of SK3 Group. "We expect it to be in high demand with collectives and consumers."
LOS ANGELES, CA -- (Marketwired) -- 10/10/2013 -- SK3 Group, Inc.'s (OTC Pink: SKTO) subsidiary, Medical Greens, is pleased to announce that it has obtained the exclusive license for Dharmanol™ for the State of California. Dr. Charles Apel of Berkeley Bio-Organic Research Laboratories has developed a proprietary technology to extract, stabilize, and preserve the medicinal cannabinoids found in hemp and marijuana in their non-psychoactive form. This technology allows patients to consume cannabinoid medicine without any of the "high" or "stoned" effects.
"We consider this to be a major breakthrough in the treatment of cancer using cannabinoids. The results seen by those groups and individuals promoting the use of what has been dubbed 'Simpson' therapy have been very convincing. The problem, however, has been that many people who are fighting cancer, and have no experience with cannabis, cannot take the emotional and mental effects that come from following the regimen, which requires consumption of a gram of cannabis extract oil every day for several months. This is the equivalent of smoking up to 100 marijuana cigarettes every day. The "high" from the experience is truly overwhelming, and we have seen patients choose to discontinue the therapy, even though doing so likely leads to negative effects on their treatment," said D. Gold, Dr. Apel's partner in development of the process. "Now patients will be able to consume the large doses necessary for this therapy to be effective, with none of the psychoactive side effects that have been such an unforgiving part of the therapy."
Dharmanol™ (pronounced DAR-mah-nol) will be available in two forms: low-dose non-psychoactive tablets and high-doses. The low-dose non-psychoactive tablets can be taken daily as a nutritional supplement to stimulate the endo-cannabinoid system, an internal system which controls and regulates many other bodily systems such as immune response. Much research has shown that there is substantial medicinal benefit in "stimulating" a compromised endo-cannabinoid system with cannabinoids, causing the other systems to work as they should.
These tablets will contain an array of the most beneficial non-psychoactive cannabinoids. Each tablet will contain 5 mg. of CBD, 5 mg. of mixed cannabinoids in their non-psychoactive form (known as mixed carboxylates) and 5 mg. of a steam-distilled mixture of the natural terpenes and terpenoids found in cannabis and hemp. The terpene element is thought to be responsible for the increased medicinal efficacy of "whole plant" cannabis preparations.
At the opposite end of the spectrum is using high dosage Dharmanol™ much like the "Simpson" therapy. High doses can be taken daily with no psychoactive effects. On observing the positive results that patients are receiving with standard Simpson therapy, most people studying cannabis medicine agree that if the dose could be increased ten or a hundred times, its already substantial efficacy against cancer will be similarly enhanced. Now this is possible thanks to the removal of the "high" from the cannabinoids in the production of Dharmanol™.
"We believe that we have crossed the bridge, so to speak, between the incredible medicinal efficacy of the cannabis plant and the world of nutraceutical supplements. Now people will be able to benefit from the substantial health-giving aspects of the cannabis plant, without the 'high' and related side effects that have kept this wonderful herb from entering the world of mainstream medicine. Dr. Apel and I would like to thank all those who have worked so hard on this project to help us develop this new technology," said Gold.
"We are pleased to have acquired this exclusive license to this important new product in the fight against disease using medical cannabis," said Artemus Mayor, President of SK3 Group. "We expect it to be in high demand with collectives and consumers."
Dharmanol™ tablets will be distributed through the collectives managed by or partnered with Medical Greens, which currently has products in over 75 collectives in the state of California. The Manufacturer's Suggested Retail Price will be $25.00 per bottle for 8 capsules.
About SK3
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
(0)
(0)SK3 Group Inc. (SKTO) Stock Research Links
Scroll down for more posts ▼